Signals Research Suite Connect
Join our upcoming Connect webinar
REGISTER NOWPrevious Webinars
Harnessing the Power of Antibody Drug Conjugates:
How the Signals™ Research Suite Advances Multi-Modal Drug Development
Most contemporary drug discovery companies (Sponsors) outsource some (or all) drug development to external contract partners, e.g., Contract Research Organizations (CROs) and/or Contract Development and Manufacturing Organizations (CDMOs). Communication between Sponsor and Contract organization is largely done via e-mail and poorly structured Excel reports which is a highly manual, inefficient, and error prone process. Additionally, Sponsors of contracted work struggle with a common set of problems and challenges including:
- Prioritizing and communicating the work to the CRO
- Onboarding and offboarding CRO resources
- Tracking the work at the CRO
- Masking proprietary information from the CRO to preserve the sponsors intellectual property
- Integrating the data from the CRO into the corporate data management systems
Historically each sponsor has been isolated to solve these problems on their own, costing time and money, but today we announce a new capability being delivered in 2024 by Revvity Signals that adds fit-for-purpose CRO collaboration capabilities to Signals Notebook and Signals Research Suite. This cutting-edge new product will leverage the Signals Platform and solve the common problems plaguing the standard sponsor-CRO interactions.
What you will learn:
- Gain insights into the administration, collaboration, IP protection, and project management challenges facing Biopharmaceutical sponsors when they externalize drug discovery research.
- Learn how Signals Synergy, a new solution from Revvity Signals, redefines collaboration between biopharmaceutical sponsors and contract partners.
- Get a glimpse of the key capabilities inside Signals Synergy.
Signals Research Suite Speakers
Heather Hayes
Signals Synergy Product Leader, Revvity Signals
Heather Hayes received her Bachelor of Engineering from Vanderbilt University, where she graduated Valedictorian from the School of Engineering. After completing her PhD in Biomedical Engineering at Georgia Institute of Technology focused on neuropharmacology and sensory modulation, she led translational studies and clinical trials for neuroplasticity-promoting therapeutics for spinal cord injury. Since joining the biotech industry, Heather has over 7 years of experience in the development and product management of high throughput screening instrumentation and stem cell disease modeling. Heather joined Revvity in 2022 to lead our initiative to enable and accelerate Sponsor-CRO collaboration workflows in the Signals Platform. She now serves as Product Leader for Signals Synergy
Chris Stumpf
Marketing Programming Manager
Chris Stumpf is a Senior Principal Marketing Professional responsible for Marketing Programs at Revvity Signals. Chris has over 20 years of experience in the Analytical Instrumentation and Informatics industry spanning Pharmaceuticals & Life Sciences to Chemicals & Materials. He has a Ph.D. in Analytical Chemistry and Mass Spectrometry from Purdue University.
Harnessing the Power of Antibody Drug Conjugates:
How the Signals™ Research Suite Advances Multi-Modal Drug Development
The Signals™ Research Suite is the first integrated informatics platform purpose-built to accelerate multi-modal drug development like ADCs and is composed of a trio of scientific software applications:
- Signals™ Notebook: The premier cloud-based electronic lab notebook that facilitates creation and communication about molecules of interest via hierarchical editing language for macromolecules (HELM), powered Chemdraw®.
- Signals™ VitroVivo: For data analysis, visualization, and curve fitting bioassay results for standardized and consistent results, powered by Spotfire®.
- Signals™ Inventa: Enabling multi-assay or multi-study comparison, powered by Spotfire, with the ability to find the best candidate to move forward, accelerating decision making. Researchers gain better visibility into ADC candidate profiling and can quickly determine structure-activity and structure-property relationships across modalities to select optimal conjugation sites and pairings.
Attendees will gain insights into the latest trends and challenges in ADC development, informed by recent research and advancements in the field. The presentation will also emphasize the importance of integrating various data types and sources in the ADC development process, showcasing how the Signals Research Suite facilitates this integration, thereby driving more efficient, safer drug development.
Signals Research Suite Speakers
Zev Wisotsky
Sr. Principal Marketing Manager for Biologics in the Signals Research Suite
Zev attended the University of California, Santa Cruz with a focus on molecular and cellular biology. He obtained his Ph.D. at the University of California, Riverside for Neuroscience where he worked on taste detection from molecular mechanism to behavioral outcomes in fruit flies. Subsequently Zev joined startup companies with the focus to support scientists getting their science done more efficiently. He has worked within pre-sales teams to discover, consult, and deliver software solutions that meet customer needs both scientifically and technically. Today he is a Revvity Senior Principle Marketing Manager for Biologics in the Signals Suite.
